# SANA — slm-full-gpu

## Metadata

ticker: SANA
arm: slm-full-gpu
judge_prompt_version: v2
context_sha256: f59616fb0331e27be1c3a2b16248dca9f180a13e4c4e9beeb74d063b2f2c56de
slm_endpoint: slm-gpu
slm_url: http://132.145.161.150:30880
slm_served_name: qwen3.6-35b-a3b-q4km
slm_artifact: ggml-org/Qwen3.6-35B-A3B-GGUF@baec3ebee244827cda0f4557eafa8b28f7545fa6:Qwen3.6-35B-A3B-Q4_K_M.gguf sha256:671e47e0ec53c665d048b98c3ecbfd5236b5ca9c3e02ed19fc8f81f7b85140c7
slm_build: b11347-5fc4f3c8c
slm_model_path: /models/Qwen3.6-35B-A3B-Q4_K_M.gguf
slm_model_ftype: Q4_K - Medium
slm_total_slots: 4
slm_n_ctx: 32768
slm_n_params: 34660610688
slm_model_size_bytes: 20408576512
slm_thinking: off
slm_sampling: {"planner": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "rag": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 2048, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "react": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "section": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 768, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "synthesis": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 4096, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.2, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}}
llm_calls: 7
llm_endpoints: slm-gpu
llm_by_site: {"rag:highlights": {"calls": 1, "completion_tokens": 575, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 9.196, "latency_s_total": 9.196, "parse_failure": 0, "prompt_tokens": 2059, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "rag:risks": {"calls": 1, "completion_tokens": 428, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 7.771, "latency_s_total": 7.771, "parse_failure": 0, "prompt_tokens": 2048, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:financial_health": {"calls": 1, "completion_tokens": 140, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 4.641, "latency_s_total": 4.641, "parse_failure": 0, "prompt_tokens": 612, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 168, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 4.979, "latency_s_total": 4.979, "parse_failure": 0, "prompt_tokens": 606, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 158, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 4.866, "latency_s_total": 4.866, "parse_failure": 0, "prompt_tokens": 502, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 138, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 4.599, "latency_s_total": 4.599, "parse_failure": 0, "prompt_tokens": 657, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 913, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 15.546, "latency_s_total": 15.546, "parse_failure": 0, "prompt_tokens": 1590, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "SANA",
  "company_name": "Sana Biotechnology, Inc.",
  "current_price": 2.89,
  "currency": "USD",
  "market_cap": 865152256.0,
  "forward_pe": -5.206176,
  "week_52_high": 6.55,
  "week_52_low": 2.61,
  "net_income": -211822000.0,
  "profit_margin": 0.0,
  "dividend_yield": 0.0,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

NEWS ARTICLES:
[
  {
    "title": null,
    "source": null,
    "published_at": null,
    "description": null
  }
]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-03-03",
    "summary": "Item 1A. Ris k Factors. Investing in shares of our common stock involves a high degree of risk. You should carefully consider the following risks and uncertainties, together with all of the other information contained in this Annual Report, including our financial statements and related notes included elsewhere in this Annual Report, before making an investment decision. The risks described below are not the only ones we face. Many of the following risks and uncertainties are, and will continue to be, exacerbated by any worsening of the global geo-political, business, and economic environment. The occurrence of any of the following risks, or of additional risks and uncertainties not presently known to us or that we currently believe to be immaterial, could materially and adversely affect o"
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-10",
    "summary": "Item 1A. Ri sk Factors Investing in shares of our common stock involves a high degree of risk. You should carefully consider the following risks and uncertainties, together with all of the other information contained in this Quarterly Report, including our financial statements and related notes included elsewhere in this Quarterly Report, before making an investment decision. The risks described below are not the only ones we face. Many of the following risks and uncertainties are, and will continue to be, exacerbated by any worsening of the global geo-political, business, and economic environment. The occurrence of any of the following risks, or of additional risks and uncertainties not presently known to us or that we currently believe to be immaterial, could materially and adversely aff"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] Based on the provided text from the SEC EDGAR filings for ticker SANA, the key takeaways regarding risk factors and business outlook include:

**1. Unproven Technology and Development Risks**
*   The company’s *ex vivo* and *in vivo* cell engineering platforms rely on novel technologies that are unproven and may not result in approvable or marketable products.
*   There are no FDA-approved therapeutics currently known that are cell products derived from pluripotent stem cells (PSCs) or utilize the company’s fusogen technology.
*   Scientific evidence supporting these platforms is preliminary, limited, and ongoing. Preclinical data is largely based on animal models and cell lines, which may not accurately predict safety and efficacy in humans.
*   Results from one cell type or microenvironment may not translate to others, and gene editing reagents may have unanticipated or undesirable effects.

**2. Regulatory and Clinical Uncertainty**
*   Preclinical and clinical testing is inherently unpredictable. The company may encounter significant challenges in creating appropriate models and assays to evaluate the safety and purity of its product candidates.
*   There is limited understanding regarding certain indications, such as autoimmune diseases, making it difficult to predict how safety and efficacy may vary across different treatments.
*   Unexpected results in testing may require changes to manufacturing processes or clinical development plans, leading to delays and increased costs.

**3. Financial and Operational Risks**
*   **Going Concern:** There is substantial doubt as to the company’s ability to continue as a going concern.
*   **Funding Needs:** The company requires additional funding to finance operations. Failure to raise capital on acceptable terms could force the delay, reduction, or elimination of product development programs or commercialization efforts.
*   **Personnel and Growth:** Success depends on retaining key personnel and recruiting qualified staff. The company may also face difficulties managing growth, including expanding development and regulatory capabilities, which could disrupt operations.

**4. Strategic and Partnership Risks**
*   The company may not realize the benefits of technologies it has acquired, in-licensed, or plans to acquire.
*   There is a risk of failing to enter into new strategic relationships or failing to realize benefits from existing ones.
*   If the company fails to successfully identify, develop, and commercialize product candidates, or experiences significant delays, its business, financial condition, and results of operations will be materially adversely affected.

**5. Forward-Looking Statements**
*   Statements regarding future events, financial trends, and business strategy are based on current expectations and estimates. They are not guarantees of future performance and are subject to significant uncertainties. Actual results may differ materially from these projections due to various risk factors, including those not currently known or deemed immaterial.

RAG — RISK FACTORS:
[From Pinecone cache] The primary risk factors disclosed include:

*   **Unproven Technology:** The company’s ex vivo and in vivo cell engineering platforms are based on novel technologies that are unproven and may not result in approvable or marketable products. There is substantial doubt regarding the feasibility of developing therapeutic treatments based on these platforms, as scientific evidence is preliminary and limited.
*   **Development and Regulatory Uncertainty:** Preclinical and clinical testing is inherently unpredictable. Results from animal models or preclinical assays may not accurately predict safety and efficacy in humans, and the company may encounter challenges in creating appropriate models and assays to satisfy regulatory authorities.
*   **Product Candidate Failure:** If the company is unable to successfully identify, develop, and commercialize product candidates, or experiences significant delays, its business, financial condition, and results of operations will be materially adversely affected.
*   **Going Concern and Funding Needs:** There is substantial doubt as to the company’s ability to continue as a going concern. The company requires additional funding to finance operations, and failure to raise capital when needed could force the delay, reduction, or elimination of product development programs or commercialization efforts.
*   **Strategic and Licensing Risks:** The company may not realize the benefits of technologies it has acquired, in-licensed, or will acquire. It may also fail to enter into new strategic relationships or realize benefits from existing ones.
*   **Personnel and Growth Management:** The company’s ability to develop its platforms and achieve future growth depends on retaining key personnel and recruiting qualified staff. Additionally, the company may encounter difficulties in managing growth, which could disrupt operations and harm the business.
*   **Novel Reagents and Materials:** The use of novel manufacturing reagents and materials may have unknown or unanticipated effects on safety, efficacy, or manufacturability, potentially affecting all programs using them and causing delays.
*   **Indication-Specific Variability:** Product candidates may reveal unexpected differences in safety or efficacy when developed for different indications compared to other candidates using the same technologies, potentially requiring changes to manufacturing or clinical development plans.

## Pre-written sections (judge input)

### Financial Health

Sana Biotechnology, Inc. (SANA) is currently trading at $2.89, reflecting a market capitalization of approximately $865.15 million. The company reports a negative forward P/E ratio of -5.21 and a net income of -$211.82 million, indicating significant operational losses. Consequently, the profit margin stands at 0%, underscoring the firm's reliance on capital raises rather than current profitability to sustain operations. While the stock remains near its 52-week low of $2.61, the absence of positive earnings highlights the high-risk nature of this pre-profit biotechnology investment.

### Recent Developments

Sana Biotechnology, Inc. has filed its 10-K annual report dated March 3, 2026, and its 10-Q quarterly report dated August 10, 2026, both of which prominently highlight significant risk factors related to the company's financial health and operational uncertainties. The filings underscore the high degree of risk associated with investing in the stock, particularly in the context of a worsening global geopolitical and economic environment. With a current stock price of $2.89 and a substantial net loss of $211.8 million, investors are cautioned to carefully weigh these adverse risks against potential future developments. The absence of recent specific news events suggests that market attention is currently focused on these regulatory disclosures and the company's ability to navigate its financial challenges.

### SEC Filing Highlights
Sana Biotechnology faces substantial doubt regarding its ability to continue as a going concern, necessitating additional capital to sustain operations and avoid delays in product development. The company’s novel *ex vivo* and *in vivo* cell engineering platforms remain unproven, with no FDA-approved therapeutics currently existing for pluripotent stem cell-derived products or its fusogen technology. Preclinical data relies heavily on animal models and cell lines, creating significant uncertainty regarding the translation of safety and efficacy to human applications. Furthermore, the business is highly dependent on retaining key personnel and successfully executing strategic partnerships, as failure to commercialize candidates could materially adversely affect its financial condition.

### Risk Factors

*   **Unproven Technology and Scientific Feasibility:** The company’s ex vivo and in vivo cell engineering platforms are based on novel technologies with preliminary scientific evidence, creating substantial doubt regarding their feasibility to produce approvable or marketable therapeutic treatments.
*   **Regulatory Uncertainty and Product Failure:** Preclinical and clinical testing is inherently unpredictable, and failure to successfully identify, develop, or commercialize product candidates due to safety, efficacy, or regulatory challenges could materially adversely affect the business.
*   **Going Concern and Funding Risks:** There is substantial doubt regarding the company’s ability to continue as a going concern, as it requires additional capital to finance operations; failure to raise funds could force the delay, reduction, or elimination of development programs.

## Audited (Exec Summary + Outlook)

### Executive Summary
Sana Biotechnology is a pre-profit biotechnology firm developing novel *ex vivo* and *in vivo* cell engineering platforms, currently trading near its 52-week low with a market capitalization of approximately $865.15 million and a substantial net loss of $211.82 million. The stock is notable now due to explicit "substantial doubt" regarding its ability to continue as a going concern, highlighting the critical dependency on securing additional capital to sustain operations. The single most important near-term variable is the company's ability to successfully raise necessary funds and execute strategic partnerships to avoid delays in product development.

### Outlook
The directional outlook for Sana Biotechnology is cautiously cautious, characterized by extreme binary risk driven by liquidity constraints and scientific validation. Key variables to monitor include the company's success in securing additional capital to address going concern doubts, the retention of key personnel, and the execution of strategic partnerships that could validate its unproven *ex vivo* and *in vivo* platforms. The thesis would be strengthened by evidence of successful clinical translation from animal models to human applications or the announcement of a definitive financing arrangement; conversely, the view would weaken significantly if the company fails to raise funds or if preclinical data continues to show limited translational potential, potentially forcing the delay or elimination of development programs.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically evaluate every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the **Executive Summary** and **Outlook** sections.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "market capitalization of approximately $865.15 million"
LABEL: SUPPORTED
REASON: The raw source data lists `market_cap: 865152256.0`, which equals approximately $865.15 million, matching the pre-written Financial Health section exactly.

---

CLAIM: "a substantial net loss of $211.82 million"
LABEL: SUPPORTED
REASON: The raw source data lists `net_income: -211822000.0`, which equals -$211.822 million, consistent with the stated $211.82 million net loss.

---

CLAIM: "currently trading near its 52-week low"
LABEL: SUPPORTED
REASON: The current price is $2.89 and the 52-week low is $2.61; $2.89 is 10.7% above the low and 55.9% below the 52-week high of $6.55, placing it arithmetically near the low end of its range, consistent with the pre-written Financial Health section's identical characterization.

---

**OUTLOOK**

The Outlook section contains no specific quantitative figures, price targets, thresholds, ratios, metrics, percentages, named product milestones, or forward-looking numbers. All content is qualitative and directional (e.g., "cautiously cautious," "extreme binary risk," "key variables to monitor," "would be strengthened," "would weaken significantly"). There are no numerical claims to audit in this section.

---

**SUMMARY**

All three quantitative claims in the Executive Summary are **SUPPORTED**. The Outlook section contains **no auditable quantitative or forward-looking numerical claims**.
